Who is sponsoring NCT03521323?

NCT03521323 is sponsored by Third Affiliated Hospital, Sun Yat-Sen University.

What condition does NCT03521323 study?

NCT03521323 studies Spinal Cord Injuries.

What drugs are being tested in NCT03521323?

Interventions: Umbilical Cord Mesenchymal Stem Cells, Placebos.

What is the status of NCT03521323?

NCT03521323 is currently UNKNOWN.

Last reviewed 2019-05-01 · How we verify

Intrathecal Transplantation of UC-MSC in Patients With Early Stage of Chronic Spinal Cord Injury

NCT03521323 PHASE2 UNKNOWN

This study aim to evaluate the safety and efficacy of intrathecal transplantation of allogeneic umbilical cord derived mesenchymal stem cells (UC-MSC) for treatment of different phrases of spinal cord injury. Here, the history of spinal cord injury is divided into three periods, Sub-acute SCI, Early stage of chronic SCI, and Late stage of chronic SCI, which is 2W-2M, 2M-12M, and more than 12M after injury, respectively. The purpose is to investigate whether the patients with spinal cord injury benefit from UC-MSC transplantation, and then find out the best time for SCI treatment. In this part of the study, the investigators will treat patients with early stage of chronic spinal cord injury with UC-MSC transplantation or placebo.

Details

Lead sponsor	Third Affiliated Hospital, Sun Yat-Sen University
Phase	PHASE2
Status	UNKNOWN
Enrolment	66
Start date	Sun Sep 01 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Fri Dec 31 2021 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Spinal Cord Injuries

Interventions

Umbilical Cord Mesenchymal Stem Cells
Placebos

Countries

China